Autonomix Medical's Novel Nerve Ablation Technique Earns Top Abstract at CRT 2026
Event summary
- Autonomix Medical's abstract on transvascular peripheral nerve neurolysis selected as Top Abstract at CRT 2026.
- Nikola Cesarovic, PhD, to present clinical feasibility and outcomes data during podium session on March 7, 2026.
- Technology aims to selectively disrupt peripheral nerve activity via transvascular approach.
- Autonomix's platform technology includes catheter-based microchip sensing array for neural signal detection.
- Company initially targeting pancreatic cancer pain treatment, with broader applications in cardiology and chronic pain management.
The big picture
Autonomix Medical's recognition at CRT 2026 highlights the growing interest in precision nerve-targeted therapies. The company's technology aims to revolutionize the treatment of diseases involving the peripheral nervous system, initially focusing on pancreatic cancer pain but with potential applications in cardiology and chronic pain management. This strategic positioning places Autonomix at the forefront of a burgeoning sector within medical device innovation.
What we're watching
- Clinical Validation
- How early feasibility findings will translate into broader clinical adoption and regulatory approval.
- Market Expansion
- Whether Autonomix can successfully expand its technology across multiple indications beyond pancreatic cancer pain.
- Competitive Positioning
- The pace at which Autonomix can differentiate itself in the growing nerve modulation market.
Related topics